Compare GSK plc (GSK) vs Wolfspeed Inc (WOLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Wolfspeed Inc — how do they compare? GSK plc trades at $46.7 (market cap $95.18B), while Wolfspeed Inc trades at $31.62 (market cap $1.66B). The key difference: GSK plc is far larger — about 57.3× Wolfspeed Inc's market cap, and GSK plc pays a 3.86% dividend while Wolfspeed Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Wolfspeed Inc for 19 Days on average.
| GSK | WOLF | |
|---|---|---|
Market Cap | $95.18B | $1.66B |
Volume | 5,852,596 | 5,963,473 |
Sector | Health | Technology |
52-Week High | $61.18 | $73.68 |
52-Week Low | $43.24 | $14.80 |
Typical Hold Time | 93 Days | 19 Days |
Enterprise Value | $115.25B | $2.37B |
Dividend Yield | 3.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 0.13% with a bearish technical signal. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 15.1 and EV/EBITDA of 9.0. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for growth beyond upcoming HIV patent expirations.
GSK presents a balanced investment case with solid profitability (29.7% ROE) offset by near-term headwinds. The stock offers value at current levels but faces execution risks from pipeline development and patent cliffs. Analyst sentiment leans cautious with 55% hold ratings, suggesting moderate upside potential with careful risk management required.
Wolfspeed (WOLF) trades at $31.37, down 1.45% on the day, with a bullish technical signal from moving averages. The company shows severe fundamental strain, with a gross profit margin of -16.05% and a net income margin of -212.41% for 2025, though 2026 projections indicate a potential turnaround to slight profitability. Recent news highlights expansion of its 200mm silicon carbide portfolio, positioning it in the growing AI and electrification markets.
The outlook is speculative, with significant upside potential if operational targets are met, but high execution risk persists. Analyst consensus is mixed with a $54.32 price target, suggesting substantial upside from current levels if the company can achieve revenue growth and margin improvement as forecasted.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Wolfspeed Inc
Wolfspeed is the global leader in wide bandgap semiconductors, specializing in silicon carbide (SiC) and gallium nitride (GaN) materials and devices. It operates a vertically integrated model, controlling the entire process from raw material substrate production to advanced power modules, serving as a critical infrastructure provider for electric vehicles (EVs), renewable energy, and AI data centers.
Read more on WOLF →
